BOULDER,
Colo., Feb. 25, 2025 /PRNewswire/ -- Enliven
Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a
clinical-stage biopharmaceutical company focused on the discovery
and development of small molecule therapeutics, today announced
that management will participate in a fireside chat at the TD Cowen
45th Annual Health Care Conference on Tuesday, March 4, 2025, at 10:30 a.m. ET.
The fireside chat will be webcast live and can be accessed by
visiting the investor relations section of the Company's website at
https://ir.enliventherapeutics.com/. The webcast will be archived
for a period of 90 days following the conclusion of the live
event.
About Enliven Therapeutics
Enliven is a clinical-stage
biopharmaceutical company focused on the discovery and development
of small molecule therapeutics to help people not only live longer,
but live better. Enliven aims to address existing and emerging
unmet needs with a precision oncology approach that improves
survival and enhances overall well-being. Enliven's discovery
process combines deep insights in clinically validated biological
targets and differentiated chemistry to design potentially
first-in-class or best-in-class therapies. Enliven is based in
Boulder, Colorado.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference-302384762.html
SOURCE Enliven Therapeutics, Inc.
